Original Article Experimental Therapy with 9-[2-(Phosphonomethoxy)ethyl]- 2,6-diaminopurine (PMEDAP): Origin of Resistance (MRP4 / MRP5 / PMEDAP resistance)

Abbreviations: DTX -docetaxel, MRP (1-5) -multiple drug resistance protein, PMEA -9-[2-(phosphonomethoxy)ethyl]adenine, PMEDAP -9-[2-(phosphonomethoxy)ethyl]-2,6-diaminopurine, RQ-RT-PCR -real-time quantitative reverse transcriptasepolymerase chain reaction, SD/Cub -Sprague-Dawley inbred rats/Charles University Biology. Abstract. The role of MRP4 and MRP5 transporters in the acyclic nucleoside phosphonate PMEDAP efflux was studied in vitro (CCRF-CEM cells) and in vivo (spontaneous transplantable T-cell lymphoma of SD/Cub inbred rats). The increased resistance against the cytostatic agent PMEDAP during longterm treatment was found to be associated with overexpression of MRP4 and MRP5 genes. The course of both gene activation differs significantly. While the MRP5 function is important in the onset of PMEDAP resistance, the intensity of the relative MRP4 gene expression increases rather continuously. Our data indicate cooperative acting of both MRP4 and MRP5 genes during the PMEDAP resistance development